The short version
- Why people research itSoft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- What the evidence isApproved with randomized data for acute muscle spasm.
- What to watchPalpitations or fainting.
How Cyclobenzaprine works
Structurally a tricyclic; acts centrally at the brainstem rather than on muscle itself. It doesn't relax the muscle directly — it reduces the tonic descending drive that keeps it spasming.
Cyclobenzaprine is a tricyclic. Not tricyclic-like — a tricyclic, one double bond in the central seven-membered ring away from amitriptyline.
The alpha-2 story in most references is wrong, and there is a clean experiment showing it. Kobayashi 1996 measured the monosynaptic reflex in rats. The alpha-2 antagonists idazoxan and yohimbine did not block that depression, and destroying noradrenergic neurons with 6-hydroxydopamine did not attenuate it either.
- Oral
On the goal map: Synovial inflammation & pain (Joints & bone)
Research on Cyclobenzaprine4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Trial-backed for acute muscle spasm; the effect fades after the first week or two.
Human clinical evidence
Approved with randomized data for acute muscle spasm. With modest positive results.
Correlative data
Wide clinical use. The consistently reported limitation is anticholinergic load — dry mouth, next-day grogginess.
How the mechanism reads
Structurally a tricyclic antidepressant, closely related to amitriptyline, acting centrally rather than on muscle directly. It antagonizes 5-HT2 receptors in the brainstem, reducing descending motor drive.
MechanisticBeing a TCA predicts the whole side-effect profile — antihistaminergic sedation, anticholinergic dryness — and the serotonergic interaction risk that its 'muscle relaxant' label rather hides.
Mechanistic
Sources
- Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems.. Eur J Pharmacol 1996 · PMID 8884233
- Honda M, Nishida T, Ono H. Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors.. Eur J Pharmacol 2003 · PMID 12498911
- Singh K, Senatorov IS, Cheshmehkani A, Karmokar PF, Moniri NH. The Skeletal Muscle Relaxer Cyclobenzaprine Is a Potent Non-Competitive Antagonist of Histamine H1 Receptors.. J Pharmacol Exp Ther 2022 · PMID 34992159
- Winchell GA. Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency.. J Clin Pharmacol 2002 · PMID 11808825
- Browning R. Cyclobenzaprine and back pain: a meta-analysis.. Arch Intern Med 2001 · PMID 11434793
- Lederman S, Arnold LM, Vaughn B, Engels JM, Kelley M, Sullivan GM. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine.. Pain Med 2025 · PMID 40627411
- Darwish M. Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.. Expert Opin Drug Metab Toxicol 2010 · PMID 20883117
- US Food and Drug Administration. FLEXERIL (cyclobenzaprine HCl) tablets - full prescribing information.. FDA approved labeling, revision 2013
- Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Announces FDA Approval of Tonmya (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia.. Company announcement, 15 August 2025
Cyclobenzaprine safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- An MAO inhibitor taken now or in the last two weeks.
- Arrhythmia, heart block or a recent heart attack, as it is structurally a tricyclic.
- Hyperthyroidism, which sensitizes the heart to tricyclics.
- Glaucoma or urinary retention, from anticholinergic action.
- Combining with tramadol, SSRIs or other serotonergic drugs.
What’s expected
- Drowsiness, dry mouth and dizziness.
- Reduced muscle spasm through brainstem action, not at the muscle.
- Constipation and next-day fog.
Watch for
- Palpitations or fainting.
- Agitation, fever and rigid muscles, the serotonin-excess pattern.
- Unable to pass urine, an anticholinergic effect on the bladder.
Labs that tell you it’s working
- Comprehensive Metabolic Panel: potassium and liver function for a tricyclic with cardiac effects.
- Magnesium: low levels worsen tricyclic rhythm risk.
Tricyclic-structure centrally acting muscle relaxant: reduces descending tonic drive, with anticholinergic, sedative and rhythm effects of its class. PMID 12498911 PMID 34992159
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Cyclobenzaprine FAQ4 common questions
- Is Cyclobenzaprine approved for human use?
- No. Cyclobenzaprine is a research compound.
- What is Cyclobenzaprine researched for?
- Soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Magnesium: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Cyclobenzaprine: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



